BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36727866)

  • 1. Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study.
    Wang G; Li L; Zang J; Hong H; Zhu L; Kung HF; Zhu Z
    Clin Nucl Med; 2023 Apr; 48(4):289-295. PubMed ID: 36727866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective head-to-head comparison of [
    Wang G; Li L; Zhu M; Zang J; Wang J; Wang R; Yan W; Zhu L; Kung HF; Zhu Z
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3126-3136. PubMed ID: 37233785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of
    Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
    J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraindividual comparison between
    Spohn S; Jaegle C; Fassbender TF; Sprave T; Gkika E; Nicolay NH; Bock M; Ruf J; Benndorf M; Gratzke C; Grosu AL; Zamboglou C
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of [
    Wang G; Hong H; Zang J; Liu Q; Jiang Y; Fan X; Zhu Z; Zhu L; Kung HF
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1052-1062. PubMed ID: 34557930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI,
    Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B
    Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
    Kulkarni SC; Sundaram PS; Padma S
    Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer.
    Chandekar KR; Singh H; Kumar R; Kumar S; Kakkar N; Mittal BR; Singh SK
    Clin Nucl Med; 2023 Jan; 48(1):e1-e8. PubMed ID: 36240786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary Evaluation of
    Lee H; Scheuermann JS; Young AJ; Doot RK; Daube-Witherspoon ME; Schubert EK; Fillare MA; Alexoff D; Karp JS; Kung HF; Pryma DA
    Mol Imaging Biol; 2022 Oct; 24(5):710-720. PubMed ID: 35349040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-Head Comparison of
    Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
    J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
    [No Abstract]   [Full Text] [Related]  

  • 17. Hybrid imaging with [
    Glemser PA; Rotkopf LT; Ziener CH; Beuthien-Baumann B; Weru V; Kopp-Schneider A; Schlemmer HP; Dimitrakopoulou-Strauss A; Sachpekidis C
    Cancer Imaging; 2022 Sep; 22(1):53. PubMed ID: 36138437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective correlation of
    Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
    Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse PSMA expression in primary prostate cancer: reason for negative [
    Cytawa W; Kircher S; Kübler H; Werner RA; Weber S; Hartrampf P; Bandurski T; Lass P; Połom W; Matuszewski M; Wester HJ; Lapa C; Rosenwald A; Seitz AK; Buck AK
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3938-3949. PubMed ID: 35556160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.